Diabetic Retinopathy: Causes, Stages, Treatment, and Prevention

What Is Diabetic Retinopathy?

Diabetic retinopathy is a microvascular complication of diabetes in which persistently high blood glucose weakens and distorts the blood vessels of the retina, the light-sensitive tissue lining the back of the eye. Damage accumulates silently over years. By the time a patient notices blurring or floaters, the structural changes may already be extensive.

The retina demands an exceptionally high oxygen supply per gram of tissue. The capillaries that deliver that oxygen are among the smallest in the human body, with walls only one or two cells thick. Sustained hyperglycemia triggers several injurious cascades: increased polyol-pathway flux, advanced glycation end-product (AGE) formation, protein kinase C activation, and oxidative stress [1]. Each pathway stiffens vessel walls, kills pericytes (the structural support cells of capillaries), and eventually causes the endothelial cells themselves to drop out, leaving acellular "ghost" vessels incapable of carrying blood.

Pericyte loss is considered the earliest pathological event. Without pericyte support, capillary walls balloon outward into microaneurysms, the first clinical sign visible on fundoscopy. Fluid leaks through these weak walls, accumulating in the layers of the retina (diabetic macular edema, or DME) or hemorrhaging outward as dot-and-blot or flame-shaped bleeding. Retinal ischemia follows, and the resulting oxygen deprivation triggers upregulation of vascular endothelial growth factor (VEGF). VEGF drives growth of fragile new vessels (neovascularization) that bleed easily and can eventually contract into fibrous bands, pulling the retina off its underlying tissue (tractional retinal detachment) [2].

Insulin resistance contributes to this process even before frank diabetes develops. Elevated fasting insulin and postprandial glucose spikes generate oxidative stress in retinal tissue, and observational data suggest sub-clinical retinal capillary changes can appear in the prediabetes range (fasting glucose 100-125 mg/dL) [3].

How Common Is Diabetic Retinopathy?

The numbers are large and growing. According to the CDC, 34.6 million Americans have diabetes as of 2021, and projections suggest roughly 11 million of them have diabetic retinopathy [4]. Globally, the International Diabetes Federation estimates that 103 million adults had DR in 2020, a figure expected to reach 160 million by 2045 [5].

Duration of diabetes is the single strongest predictor of prevalence. After 20 years of type 1 diabetes, nearly all patients show some retinal change; roughly 60% of type 2 patients do after the same duration [6]. Prevalence also tracks glycemic control tightly, which is why the landmark trials below changed clinical practice so decisively.

The Four Stages of Diabetic Retinopathy

Clinicians classify DR using the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale, often simplified into four clinical stages [7].

Stage 1: Mild nonproliferative DR (NPDR). Microaneurysms only. No symptoms. Vision usually normal. Annual screening is sufficient if glycemic control is good.

Stage 2: Moderate NPDR. More microaneurysms, dot-and-blot hemorrhages, hard exudates, and sometimes cotton-wool spots (nerve-fiber layer infarcts). DME may begin here. Screening every 6 months is often recommended.

Stage 3: Severe NPDR. The "4-2-1" rule defines this stage: more than 20 intraretinal hemorrhages in each of 4 quadrants, venous beading in 2 or more quadrants, or intraretinal microvascular abnormalities (IRMA) in at least 1 quadrant. Roughly 52% of eyes with severe NPDR progress to proliferative disease within 1 year without treatment [7].

Stage 4: Proliferative DR (PDR). New vessels grow on the disc or elsewhere on the retina. Vitreous or pre-retinal hemorrhage and fibrovascular proliferation carry a high risk of sudden, severe vision loss. This is the stage at which panretinal photocoagulation or anti-VEGF therapy becomes urgent.

Diabetic macular edema can occur at any stage and is the most common cause of moderate vision loss in DR. The ETDRS defined clinically significant macular edema (CSME) as retinal thickening at or within 500 microns of the center of the macula [7].

The Evidence That Glycemic Control Protects the Retina

Tight blood sugar management is the most powerful tool for prevention. Two landmark randomized controlled trials established this beyond reasonable doubt.

The Diabetes Control and Complications Trial (DCCT, N=1,441) compared intensive insulin therapy (HbA1c target: below 7%) versus conventional therapy (HbA1c averaging 9.1%) in type 1 diabetes over a mean of 6.5 years. Intensive therapy reduced the risk of retinopathy development by 76% and slowed progression of existing retinopathy by 54% [8]. Those results held in the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study, which showed that the protective benefit persisted for more than a decade after HbA1c values in the two groups converged, a phenomenon called "metabolic memory" [9].

The UK Prospective Diabetes Study (UKPDS, N=5,102) provided parallel evidence in type 2 diabetes. Each 1-percentage-point reduction in HbA1c was associated with a 37% reduction in microvascular complications, including retinopathy requiring photocoagulation [10].

The American Diabetes Association (ADA) 2024 Standards of Care state: "Lowering A1C to below or around 7% has been shown to reduce microvascular complications of diabetes, including diabetic retinopathy" [11]. For patients with established cardiovascular disease or hypoglycemia unawareness, individualized targets may be appropriate, but the directional evidence consistently favors lower glucose.

Blood pressure control adds an independent protective effect. In UKPDS, tight blood pressure control (mean 144/82 mmHg vs. 154/87 mmHg) reduced the risk of deterioration in visual acuity by 47% [10].

Screening: Who Needs It, When, and How

Annual dilated fundus examination is the standard for most patients with diabetes. The ADA 2024 guidelines specify [11]:

• Type 1 diabetes: first exam within 5 years of diagnosis, then annually.
• Type 2 diabetes: dilated eye exam at the time of diagnosis, then annually.
• Pregnancy with pre-existing diabetes: exam in the first trimester, then every trimester and for 1 year postpartum, because pregnancy accelerates retinopathy progression.

A single normal examination does not eliminate risk. Retinal status can change substantially in 12 months if glycemic or blood pressure control deteriorates. Patients with no retinopathy and consistently well-controlled HbA1c (below 7%) may extend the interval to every 2 years after discussion with their ophthalmologist, per ADA guidance [11].

Validated AI-based retinal imaging programs have received FDA clearance as screening adjuncts. IDx-DR (now called LumineticsCore) was the first autonomous AI diagnostic system cleared by the FDA in 2018 for detecting more than mild DR [12]. Point-of-care fundus cameras using this technology allow primary care clinics to screen patients without requiring an ophthalmology referral for the initial screen, though any positive result still triggers a full exam.

Treating Diabetic Macular Edema

DME affecting the center of the macula is the leading cause of vision loss in DR. Center-involving DME is now treated first with intravitreal anti-VEGF injections rather than laser, based on data from the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T trial (N=660) [13].

Protocol T compared three anti-VEGF agents at 2 years:

• Aflibercept 2 mg: mean improvement of 12.8 letters (ETDRS chart)
• Ranibizumab 0.3 mg: mean improvement of 12.7 letters
• Bevacizumab 1.25 mg: mean improvement of 10.0 letters

When baseline visual acuity was 20/50 or worse, aflibercept showed a statistically significant advantage (P<0.001 vs. bevacizumab; P<0.05 vs. ranibizumab) [13]. For eyes with better baseline acuity (20/32 to 20/40), all three agents produced similar outcomes.

Faricimab (Vabysmo), a bispecific antibody targeting both VEGF-A and angiopoietin-2, received FDA approval in January 2022 for DME and neovascular AMD. The YOSEMITE (N=940) and RHINE (N=951) phase 3 trials showed faricimab every 16 weeks was non-inferior to aflibercept every 8 weeks, with roughly 45% of faricimab patients achieving a 16-week dosing interval [14]. Reduced injection frequency matters for patients who face transportation barriers or significant injection burden.

Focal or grid laser photocoagulation remains an option for non-center-involving CSME or as adjunct therapy to reduce injection frequency, but it is no longer the primary treatment for center-involving DME.

Treating Proliferative Diabetic Retinopathy

Panretinal photocoagulation (PRP) has been the standard of care for high-risk PDR since the Diabetic Retinopathy Study (DRS) demonstrated a 50% reduction in severe vision loss in 1976 [15]. PRP destroys peripheral retinal tissue to reduce the overall metabolic demand and VEGF production of the retina, causing regression of new vessels.

DRCR.net Protocol S (N=305) showed that intravitreal ranibizumab was non-inferior to PRP for visual acuity outcomes in PDR over 5 years, with better preservation of peripheral visual field and lower rates of DME development [16]. Anti-VEGF therapy is now preferred in eyes with center-involving DME and PDR together, and is an acceptable alternative to PRP in PDR alone, provided the patient can reliably attend monthly injection visits.

Vitrectomy is reserved for tractional retinal detachment involving or threatening the macula, non-clearing vitreous hemorrhage, or advanced fibrovascular proliferation not amenable to laser or injection therapy.

Insulin Resistance, Prediabetes, and the Eye

Retinal changes can appear before a formal diabetes diagnosis. A 2018 population-based study using data from the UK Biobank (N=80,000+) found that individuals with impaired fasting glucose had measurably thinner retinal nerve-fiber layers and more microaneurysm-like lesions than normoglycemic controls, even after adjusting for age, BMI, and blood pressure [3]. This suggests that oxidative stress and endothelial dysfunction begin in the prediabetes range, long before retinopathy becomes clinically detectable.

Insulin resistance (defined by HOMA-IR above 2.5 in most research cohorts) promotes retinal damage through several overlapping mechanisms: elevated circulating insulin itself may directly stimulate IGF-1 receptors on retinal endothelium, while the dyslipidemia and hypertension that accompany insulin resistance add independent vascular stress [1]. The practical takeaway is that people with prediabetes should not wait for a diabetes diagnosis to begin retinal surveillance; a baseline fundus exam and annual metabolic monitoring are prudent.

The HealthRX Retinopathy Risk Stratification Framework assigns screening urgency based on three variables: current HbA1c, duration of diabetes, and presence of hypertension or dyslipidemia. Patients meeting two or more of the following criteria (HbA1c above 8%, diabetes duration above 10 years, systolic BP above 140 mmHg, or LDL above 130 mg/dL) are flagged for every-6-month ophthalmology review rather than annual screening, in alignment with AAO Preferred Practice Patterns. This framework will be incorporated into the HealthRX clinical intake workflow in Q3 2025.

The Role of Lipid Control and Other Risk Factors

Blood sugar and blood pressure get most of the attention, but dyslipidemia independently accelerates retinopathy. The FIELD trial (N=9,795) found that fenofibrate (160 mg daily) reduced the need for laser treatment by 31% in type 2 diabetes patients compared with placebo [17]. The ACCORD Eye Study (N=2,856) confirmed these findings, showing that fenofibrate plus simvastatin reduced DR progression by 40% compared with simvastatin alone [18]. Current AAO and ADA guidelines list fenofibrate as a reasonable adjunct in patients with DR who are already on statin therapy.

Smoking cessation, anemia correction, and renal protection (ACE inhibitors or ARBs for patients with microalbuminuria) round out the systemic risk-factor management that every patient with DR should receive.

What Patients Need to Know About Symptoms and When to Seek Care

Early-stage DR is asymptomatic. Patients with type 1 or type 2 diabetes who report any of the following should be evaluated by an ophthalmologist within 24-48 hours, not at their next scheduled annual visit:

• Sudden increase in floaters or new onset of floaters
• A curtain or shadow across part of the visual field
• Sudden, painless decrease in visual acuity in one or both eyes
• Flashes of light not previously present

These symptoms may indicate vitreous hemorrhage, tractional retinal detachment, or rapidly progressive PDR, all of which require urgent intervention to preserve vision.

Systemic Medications That May Affect Retinopathy

Several drug classes relevant to HealthRX patients interact with retinopathy risk or treatment:

GLP-1 receptor agonists: The SUSTAIN-6 trial (N=3,297) found that semaglutide 0.5 mg and 1 mg weekly were associated with a 76% higher rate of DR complications compared with placebo in patients with pre-existing retinopathy and high HbA1c [19]. This is believed to reflect rapid HbA1c lowering in a retina already adapted to high glucose (analogous to the early worsening seen with intensive insulin therapy in DCCT). The FDA label for semaglutide products carries a warning. Patients with moderate-to-severe NPDR or PDR who are starting a GLP-1 agonist should have a baseline ophthalmology exam and a follow-up exam 3-4 months after initiation.

Thiazolidinediones (TZDs): These insulin-sensitizing agents (pioglitazone, rosiglitazone) may increase fluid retention and macular edema risk. Patients on TZDs with pre-existing DME warrant closer monitoring.

Metformin: No direct evidence links metformin to worsening retinopathy; observational data from a 2021 retrospective cohort (N=32,456) in Taiwan even suggested a modest protective association, possibly through AMPK activation [20]. However, metformin is contraindicated when eGFR falls below 30 mL/min/1.73m2, a threshold often reached in patients with advanced diabetic nephropathy who may also have advanced retinopathy.

Monitoring After Treatment: What "Success" Looks Like

Anti-VEGF therapy for DME aims for resolution of central subfield thickness (CST) on OCT to below 250 microns and improvement of best-corrected visual acuity (BCVA) by at least 5 ETDRS letters (one line). Most patients require monthly injections for the first 6 months, then transition to a treat-and-extend protocol, spacing injections by 2-week increments as the retina remains dry.

Retreatment is indicated when OCT shows recurrent subretinal or intraretinal fluid, or when BCVA drops by 5 or more ETDRS letters from the best achieved response. Stopping anti-VEGF therapy prematurely is a common error; the DRCR.net Protocol I 5-year data showed that eyes that stopped treatment before 3 years were significantly more likely to lose the vision gains achieved [21].

The ADA recommends that patients with diabetes maintain an HbA1c below 7%, blood pressure below 130/80 mmHg, and LDL cholesterol below 100 mg/dL. Achieving all three targets together produces substantially greater retinal protection than any single target alone.